Last reviewed · How we verify
NCT07374822
Real-World Study of Helicobacter Pylori Eradication Success and Its Determinants
trial testing No Study-Assigned Intervention in HELICOBACTER PYLORI INFECTIONS in 3,000 participants. Completed in 31 May 2025.
31 May 2025
Quick facts
| Lead sponsor | Run-hua Li |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 3,000 |
| Start date | 1 May 2024 |
| Primary completion | 31 May 2025 |
| Estimated completion | 31 May 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- No Study-Assigned Intervention
Conditions studied
- HELICOBACTER PYLORI INFECTIONS — all drugs for HELICOBACTER PYLORI INFECTIONS →
Sponsor
Run-hua Li
Who can join
14 and older, any sex, with HELICOBACTER PYLORI INFECTIONS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the real-world effectiveness of different treatment regimens used to eradicate Helicobacter pylori (H. pylori) infection in routine clinical practice. H. pylori is a common bacterial infection that can lead to chronic gastritis, peptic ulcers, and gastric cancer. Treatment success varies widely in real-world settings due to factors such as antibiotic resistance, patient characteristics, and treatment adherence. This retrospective observational study will review medical records of patients who underwent H. pylori testing and/or eradication treatment at Shenzhen Hospital of Southern Medical University between 2016 and 2023. No additional tests, visits, or interventions will be performed beyond standard clinical care. The study will collect information on demographics, comorbidities, treatment regimens, test results, and eradication outcomes. The primary goal is to determine the real-world eradication success rate of commonly used treatment regimens. A secondary goal is to identify factors that may influence treatment effectiveness. Findings from this study may help clinicians choose more effective treatment strategies and improve patient outcomes in everyday clinical practice.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07374822
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HELICOBACTER PYLORI INFECTIONS
Currently open trials in the same condition.
- NCT07293910 — Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Py · Phase 2 · recruiting
- NCT07335406 — Registry for the Management of Helicobacter Pylori Infection in Shandong Province · recruiting
- NCT07346521 — Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett's Mucosa Durin · recruiting
- NCT07246681 — Lignin in Treatment of Helicobacter Pylori Infection · Phase 3 · active not recruiting
- NCT07179159 — Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication · NA · recruiting
Other Run-hua Li trials
Trials by the same sponsor.
- NCT07351890 — Diagnostic Accuracy of EUS for Colorectal Submucosal Masses · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07374822 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Run-hua Li
- Last refreshed: 29 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07374822.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing